Table of Contents
Conference Papers in Medicine
Volume 2013, Article ID 804764, 4 pages
http://dx.doi.org/10.1155/2013/804764
Conference Paper

Renal Denervation Therapy: Indications and Success Factors

1Department of Cardiology and Angiology, Cardiac Catheterisation Laboratory, Charité Campus Mitte (CCM), Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
2Department of Cardiology Campus Virchow Klinikum (CVK) and Division of Emergency Medicine CVK, CCM, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany

Received 17 January 2013; Accepted 22 April 2013

Academic Editors: A. Bellou, E. Giannitsis, and C. Hamm

This Conference Paper is based on a presentation given by Karl Stangl at “Clinical Decisions in Acute Patients: ACS–POCT–Hypertension and Biomarkers” held from 19 October 2012 to 20 October 2012 in Berlin, Germany.

Copyright © 2013 Karl Stangl et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Arterial hypertension is a common and an increasing health care problem. In Germany and other Western countries, prevalence rates are as high as 50%. Of these, 13% of patients suffer from refractory hypertension, where the target blood pressure is not achievable with >3 antihypertensive substances. Renal denervation therapy (RDT) is a relatively new, catheterization-based intervention to treat patients with refractory hypertension. The rationale of RDT is the mechanical destruction with high frequency ablation of renal sympathetic fibers, which can be easily accessed via the renal artery. The first clinical trials evaluating effect and safety of the procedure have been promising, and RDT is being routinely used in specialized centers.